Our investigation of genomic integrity and preclinical studies further demonstrated the safety of this approach and provide the information and rationale for the translation of the CRISPR-Cas9-targeted IL2RG insertion approach to treat XSCID patients. Here, IL2RG is linked to T-B+ severe combined immunodeficiency due to gamma chain deficiency.